vs
PATTERSON UTI ENERGY INC（PTEN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
PATTERSON UTI ENERGY INC的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），Revvity净利率更高（12.7% vs -2.2%，领先14.9%），Revvity同比增速更快（5.9% vs -12.7%），过去两年Revvity的营收复合增速更高（9.0% vs -8.4%）
帕特森UTI能源是领先的油田服务供应商，主营陆上合同钻井、压力泵送、完井及相关配套服务，核心市场覆盖北美地区，主要服务上游油气开采企业，业务聚焦页岩气、致密气等非常规资源开发领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PTEN vs RVTY — 直观对比
营收规模更大
PTEN
是对方的1.4倍
$772.1M
营收增速更快
RVTY
高出18.6%
-12.7%
净利率更高
RVTY
高出14.9%
-2.2%
两年增速更快
RVTY
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $-24.5M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -2.2% | 12.7% |
| 营收同比 | -12.7% | 5.9% |
| 净利润同比 | -170.8% | 3.9% |
| 每股收益（稀释后） | $-0.06 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PTENRVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.2B | $698.9M | ||
| Q2 25 | $1.2B | $720.3M | ||
| Q1 25 | $1.3B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M |
净利润PTENRVTY
| Q1 26 | $-24.5M | — | ||
| Q4 25 | $-9.2M | $98.4M | ||
| Q3 25 | $-36.4M | $46.7M | ||
| Q2 25 | $-49.1M | $53.9M | ||
| Q1 25 | $1.0M | $42.2M | ||
| Q4 24 | $-51.4M | $94.6M | ||
| Q3 24 | $-978.8M | $94.4M | ||
| Q2 24 | $11.1M | $55.4M |
毛利率PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | -0.0% | 14.5% | ||
| Q3 25 | -2.4% | 11.7% | ||
| Q2 25 | -2.4% | 12.6% | ||
| Q1 25 | 1.3% | 10.9% | ||
| Q4 24 | -2.7% | 16.3% | ||
| Q3 24 | -73.8% | 14.3% | ||
| Q2 24 | 3.4% | 12.4% |
净利率PTENRVTY
| Q1 26 | -2.2% | — | ||
| Q4 25 | -0.8% | 12.7% | ||
| Q3 25 | -3.1% | 6.7% | ||
| Q2 25 | -4.1% | 7.5% | ||
| Q1 25 | 0.1% | 6.4% | ||
| Q4 24 | -4.5% | 13.0% | ||
| Q3 24 | -72.9% | 13.8% | ||
| Q2 24 | 0.8% | 8.0% |
每股收益（稀释后）PTENRVTY
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $-0.01 | $0.86 | ||
| Q3 25 | $-0.10 | $0.40 | ||
| Q2 25 | $-0.13 | $0.46 | ||
| Q1 25 | $0.00 | $0.35 | ||
| Q4 24 | $-0.10 | $0.77 | ||
| Q3 24 | $-2.50 | $0.77 | ||
| Q2 24 | $0.03 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.2B | $7.3B |
| 总资产 | $5.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | $418.5M | $919.9M | ||
| Q3 25 | $184.8M | $931.4M | ||
| Q2 25 | $183.8M | $991.8M | ||
| Q1 25 | $223.1M | $1.1B | ||
| Q4 24 | $239.2M | $1.2B | ||
| Q3 24 | $113.4M | $1.2B | ||
| Q2 24 | $72.4M | $2.0B |
总债务PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — |
股东权益PTENRVTY
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $7.3B | ||
| Q3 25 | $3.2B | $7.4B | ||
| Q2 25 | $3.3B | $7.6B | ||
| Q1 25 | $3.4B | $7.6B | ||
| Q4 24 | $3.5B | $7.7B | ||
| Q3 24 | $3.6B | $7.9B | ||
| Q2 24 | $4.6B | $7.9B |
总资产PTENRVTY
| Q1 26 | $5.4B | — | ||
| Q4 25 | $5.6B | $12.2B | ||
| Q3 25 | $5.5B | $12.1B | ||
| Q2 25 | $5.6B | $12.4B | ||
| Q1 25 | $5.8B | $12.4B | ||
| Q4 24 | $5.8B | $12.4B | ||
| Q3 24 | $6.0B | $12.8B | ||
| Q2 24 | $7.0B | $13.4B |
负债/权益比PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.38× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 4.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PTENRVTY
| Q1 26 | $63.9M | — | ||
| Q4 25 | $397.5M | $182.0M | ||
| Q3 25 | $215.8M | $138.5M | ||
| Q2 25 | $139.7M | $134.3M | ||
| Q1 25 | $208.1M | $128.2M | ||
| Q4 24 | $315.8M | $174.2M | ||
| Q3 24 | $296.3M | $147.9M | ||
| Q2 24 | $197.5M | $158.6M |
自由现金流PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | $259.0M | $161.8M | ||
| Q3 25 | $71.3M | $120.0M | ||
| Q2 25 | $-4.5M | $115.5M | ||
| Q1 25 | $46.3M | $112.2M | ||
| Q4 24 | $175.5M | $149.8M | ||
| Q3 24 | $115.7M | $125.6M | ||
| Q2 24 | $67.0M | $136.6M |
自由现金流率PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | 22.6% | 21.0% | ||
| Q3 25 | 6.1% | 17.2% | ||
| Q2 25 | -0.4% | 16.0% | ||
| Q1 25 | 3.7% | 16.9% | ||
| Q4 24 | 15.3% | 20.5% | ||
| Q3 24 | 8.6% | 18.4% | ||
| Q2 24 | 5.0% | 19.7% |
资本支出强度PTENRVTY
| Q1 26 | 4.9% | — | ||
| Q4 25 | 12.1% | 2.6% | ||
| Q3 25 | 12.3% | 2.6% | ||
| Q2 25 | 11.9% | 2.6% | ||
| Q1 25 | 12.8% | 2.4% | ||
| Q4 24 | 12.2% | 3.4% | ||
| Q3 24 | 13.5% | 3.3% | ||
| Q2 24 | 9.8% | 3.2% |
现金转化率PTENRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 207.11× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 17.83× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PTEN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
